Amolyt Pharma

Established: 2014

Country: France

Region: Lyon

Investors: Sofinnova Partners

Amolyt Pharma represents a major European VC success story – a French company created and incubated by a pioneering entrepreneur, backed by top European investors, including Sofinnova Partners, who led the company’s €130M series C in 2023, with participation from Intermediate Capital Group, Tekla Capital Investment LLC, CTI Life Sciences along with existing investors Andera Partners, Novo Holdings (Novo Ventures), Kurma Partners, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital.

In less than five years, Amolyt has built a late-stage portfolio of therapeutic peptides with the potential to address significant unmet needs for rare endocrine and related diseases. Eneboparatide (AZP-3601) is a long-acting PTH1 receptor agonist that is a potential treatment for hypoparathyroidism. The company’s pipeline also includes AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.

Amolyt Pharma aims to deliver life-changing treatments, offering hope to patients worldwide suffering by rare endocrine and related diseases.

Sofinnova Partners stepped in to lead financial support in a critical growth moment, enabling us to accelerate the successful development of Amolyt's therapeutic peptides portfolio with the potential to address significant unmet needs for rare endocrine diseases. We are grateful for the support from our investor syndicate for their continued confidence in our team and for their support of our strategy to build a global and sustainable rare disease company. Now we look forward to developing our portfolio as part of Alexion, AstraZeneca Rare Disease, an organization with proven expertise and a successful track-record in bringing innovative therapies to patients with rare diseases.

employees

€212m

raised from VCs in total

$1.05bn

acquisition agreement with AstraZeneca, expected in Q3 2024

Amolyt’s success exemplifies the track record of the Sofinnova Crossover Strategy in supporting late-stage biotech through their pivotal stages of growth. We are honored to have been part of Amolyt's journey from a promising startup to a beacon of hope for patients with rare endocrine diseases.

Key achievements

Creation of the company: 2014
Number of offices: Two – locations in Boston and Lyon
Pipeline: 3 products in the pipeline

Funding history

Seed (Alizé Pharma) in Feb 2015/May 2017 – Total: €3.2M
Round A (Alizé Pharma 3) in July 2019: €67M
Round B in September 2021: €67.6M
Round C in January 2023: €130M
Pharma Acquisition in March 2024: AstraZeneca €800M upfront at closing and €250M milestone payment upon defined regulatory milestone (undisclosed)